Paradigm-shifting platforms II, Non-IO: Targeting Better, Targeting the Intractable

Cancer Progress 2020
Tuesday, May 5th, 2020
11:45 – 1:00 PM

Moderator: James T. Lee, PhD, Principal, Oncology Lead, Cello Health BioConsulting, previously Defined Health


  • Robert A Copeland, PhD, President & CSO, Accent Therapeutics, Inc.
  • Chris LeMasters, Former EVP and CBO, Mirati Therapeutics
  • Vicky Richon, PhD, President & CEO, Ribon Therapeutics
  • Mark Rolfe, PhD, SVP, BMS
  • Tingting Zhang-Kharas, PhD, Oncology External Innovation Advisor, Loxo Oncology at Lilly
[ View Summary ]